The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
European Commission grants European marketing authorization to brexucabtagene autoleucel for the treatment of patients with R/R B-ALL
On September 6, 2022, it was announced that brexucabtagene autoleucel (brexu-cel) received European marketing authorization from the European Commission for the treatment of patients aged ≥26 years with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).1
The approval is based on results from the ZUMA-3 phase I/II trial (NCT02614066).
- Brexu-cel showed durable efficacy and a manageable safety profile in adult patients with R/R B-ALL.
- With a median follow-up of 26.8 months, 71% of evaluable patients achieved complete remission or complete remission with incomplete hematologic recovery.
- In an extended dataset of all pivotal dosed patients (n = 78), the median overall survival was >2 years and almost 4 years for responders (patients who achieved complete remission or complete remission with incomplete hematologic recovery).
- The median duration of remission was 18.6 months for efficacy-evaluable patients.
- No new safety signals were reported.
Given the high relapse rate, low survival rate, and high treatment burden in adult patients with B-ALL, this meaningful clinical development will be beneficial in addressing an unmet need in this population.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
